NCT01621373

Brief Summary

The aim of the study is to explore the optimal propofol dose in neonates receiving a single intravenous propofol bolus for endotracheal intubation during (semi-)elective INSURE (intubation-surfactant-extubation) procedure (preterm neonates) and (semi-)elective non-INSURE procedures (term-preterm neonates).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Aug 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 8, 2012

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 18, 2012

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2012

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2014

Completed
10.1 years until next milestone

Results Posted

Study results publicly available

July 30, 2024

Completed
Last Updated

July 30, 2024

Status Verified

August 1, 2012

Enrollment Period

1.9 years

First QC Date

June 8, 2012

Results QC Date

April 14, 2023

Last Update Submit

July 29, 2024

Conditions

Keywords

neonatologyintratracheal intubationpropofol

Outcome Measures

Primary Outcomes (1)

  • Effective Dose for 50% of Patients for Succesful Intubation and Subsequent Extubation in Case of Planned Extubation After INSURE Procedure

    An up-and-down dose-response design was used to calculate ED50 (mg/kg) in strata with effective sampling size of at least 6, by use of the Dixon-Massey method for small samples.

    1 hour after propofol administration

Other Outcomes (1)

  • Intubation Condition Score

    After final intubation.

Study Arms (1)

propofol

OTHER

All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.

Drug: propofol administration

Interventions

Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.

Also known as: Diprivan
propofol

Eligibility Criteria

Age1 Day - 28 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Patients can be included if they are hemodynamically stable and did not receive sedative or analgesic agents during the previous 24 hours.

You may not qualify if:

  • Known propofol intolerance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Neonatal Intensive Care Unit UZ Leuven

Leuven, Vlaams Brabant, 3000, Belgium

Location

Related Publications (1)

  • Smits A, Thewissen L, Caicedo A, Naulaers G, Allegaert K. Propofol Dose-Finding to Reach Optimal Effect for (Semi-)Elective Intubation in Neonates. J Pediatr. 2016 Dec;179:54-60.e9. doi: 10.1016/j.jpeds.2016.07.049. Epub 2016 Sep 2.

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse ReactionsInfant, Newborn, Diseases

Interventions

Propofol

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Results Point of Contact

Title
Liesbeth Thewissen, MD, PhD
Organization
UZ Leuven, NICU

Study Officials

  • Liesbeth Thewissen, MD

    UZ Leuven, Belgium

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 8, 2012

First Posted

June 18, 2012

Study Start

August 1, 2012

Primary Completion

July 1, 2014

Study Completion

July 1, 2014

Last Updated

July 30, 2024

Results First Posted

July 30, 2024

Record last verified: 2012-08

Locations